Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
Status:
Withdrawn
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate the efficacy of ibrutinib in combination with bortezomib
in in MCL (mantle cell lymphoma) patients who relapsed on single agent ibrutinib.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center